U C B SA (UCB.BR)
45.99EUR
11:35am EDT
€1.75 (+3.96%)
€44.24
€44.42
€45.99
€44.15
467,267
240,166
€50.24
€38.01
About
Overall
| Beta: | 0.51 |
| Market Cap (Mil.): | €8,113.90 |
| Shares Outstanding (Mil.): | 183.43 |
| Dividend: | 0.76 |
| Yield (%): | 1.73 |
Financials
| UCB.BR | Industry | Sector | |
|---|---|---|---|
| P/E (TTM): | 35.42 | 38.06 | 37.87 |
| EPS (TTM): | 1.25 | -- | -- |
| ROI: | 3.11 | 19.42 | 18.70 |
| ROE: | 5.14 | 20.10 | 19.53 |
UCB H1 core profit below expectation on sluggish Vimpat sales
BRUSSELS, July 31 - Belgian pharmaceutical group UCB reported first half core profit below expectations due to lower-than-expected sales of epilepsy drug Vimpat and higher research expenses.
UCB says U.S. FDA committee recommends its drug Cimzia for new uses
BRUSSELS - Belgian pharmaceutical group UCB SA said a committee of the U.S. Food and Drug Administration voted in favor of allowing UCB's arthritis drug Cimzia to be used to treat adults with active axial spondyloarthritis.
FDA panel narrowly backs new use of UCB's arthritis drug
- A panel of advisers to the U.S. Food and Drug Administration narrowly recommended approving Belgian drugmaker UCB SA's rheumatoid arthritis drug for an additional indication.
BRIEF-UCB announces new partnership neurology research
BRUSSELS, June 11 - UCB S.A. : * Says to collaborate with crelux and 4sc discovery to meet unmet needs in
UCB suffers as cold weather delays hay fever season
BRUSSELS, April 25 - Belgian drugmaker UCB had a difficult first quarter as cold spring weather in Europe meant fewer hay fever sufferers were buying its allergy medicines, it said on Thursday.
UCB reaches maximum 250 mln euros with retail bond sale
BRUSSELS, March 27 - Belgium-based drugmaker UCB said it has raised the maximum 250 million euros ($321.47 million) it was aiming for by selling a retail bond on the Brussels stock exchange to help refinance its debt.
BRIEF-UCB, Five Prime Therapeutics collaborate
BRUSSELS, March 19 - UCB S.A. : * UCB and Five Prime Therapeutics announce strategic discovery
UCB says had positive trial for Vimpat as monotherapy
BRUSSELS - Belgian pharmaceutical company UCB said on Tuesday its new epilepsy treatment Vimpat had produced promising results in a Phase III trial into its use without other drugs.
Earnings vs.
Estimates
Analyst Research Reports
| Report Title | Price |
|---|---|
|
Provider: Reuters Investment Profile
|
$20.00
|
|
Provider: Wright Reports
|
$472.00
|
|
Provider: Datamonitor
|
$175.00
|
|
Provider: GlobalData
|
$125.00
|
|
Provider: GlobalData
|
$125.00
|
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

